hepatitis C

Weighing Hepatitis C virus hold on membranes

harminka — Mon, 20 Oct 2008 11:56:25 -0500

Hepatitis C affects around 150 million people worldwide and is a major cause of chronic liver disease. Current treatment involves the anti-viral drugs interferon and ribavirin, both of which have serious side effects.

Tibotec begins enrollment for Phase III study of telaprevir

harminka — Wed, 15 Oct 2008 11:34:35 -0500

REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current standard of care, including null responders -

Liver damage in hepatitis C patients could be treated with warfarin

harminka — Fri, 01 Aug 2008 14:43:20 -0500

The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

Researchers disprove long-standing belief about HIV treatment

harminka — Fri, 25 Jul 2008 02:30:33 -0500

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."

Natalie Cole Reveals Having Hepatitis C

admin_huliq — Wed, 16 Jul 2008 11:32:54 -0500

Natalie Cole, the 58-year-old Grammy award winning singer, has announced her diagnosis with hepatitis C.

How to increase chances of remaining virus free Pakistani patients with HCV?

harminka — Wed, 21 May 2008 10:37:21 -0500

Hepatitis C is a health care problem all over the world, with 130 million patients infected the world over. The treatment is expensive and has variable results according to the genotype of the infecting virus. The first land mark in treatment is the virus clearance at the end of the treatment called End Treatment Response (ETR), but many of the patients achieving the ETR have a relapse within the next six months

Positive findings in treating patients with advanced hepatitis

harminka — Thu, 24 Apr 2008 10:20:36 -0500

The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

Dramatic rise in hepatitis C-related deaths in United States

harminka — Tue, 25 Mar 2008 13:48:26 -0500

Hepatitis C-related deaths in the United States increased by 123 percent from 1995 through 2004, the most recent year for which data are available. Mortality rates peaked in 2002, then declined slightly overall, while continuing to rise among people 55 to 64 years old.

Scientists develop a process to disrupt hepatitis C virion production

harminka — Fri, 21 Mar 2008 14:29:28 -0500

HCV is a significant human pathogen, infecting more than three percent of the world’s population. The incidence of infection in the United States has been estimated to be as high as 4 million cases.

New hope for hepatitis C sufferers

harminka — Thu, 07 Feb 2008 12:36:53 -0600

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

Shorter HCV treatment shows notable success

harminka — Thu, 03 Jan 2008 06:08:17 -0600

Two new randomized controlled trials show that treating Hepatitis C (HCV) with peginterferon and ribavirin for shorter durations can yield success rates similar to those from longer treatment lengths, with cost-savings and lower risk of serious side effects.

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

harminka — Fri, 28 Dec 2007 14:57:46 -0600

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need.